Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
7 ‘Smart Money' Stocks Set to Explode Higher
03:58pm, Saturday, 30'th Sep 2023
In the dynamic world of investing, there's always a buzz surrounding “smart money” stocks. This excitement isn't just about fleeting market trends; it's rooted in the savvy market decisions made b
GSK: Strong Positioning And Trading At Historical Discount
02:27pm, Friday, 29'th Sep 2023
GSK is a leading biopharmaceutical company with a focus on vaccines and products for major diseases. GSK's drug line-up is safe and profitable, with competitors facing larger sales loss exposure due t
GSK lifts growth ambitions for HIV business on long-acting drug
09:05am, Thursday, 28'th Sep 2023
GSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating
Explainer: What you need to know about RSV and the new vaccines
12:29pm, Friday, 22'nd Sep 2023
Advisers to the U.S. Centers for Disease Control and Prevention (CDC) are meeting on Friday to discuss recommendations for use of the first vaccine for respiratory syncytial virus (RSV) approved for p
Merck Vs. GSK: The Game-Changer Race In Pharma Excellence
12:14pm, Friday, 22'nd Sep 2023
Despite the increasing number of emerging challenges for the pharmaceutical industry, the management teams at GSK and Merck are successfully coping with them. GSK's revenue was $9.12 billion in the se
GSK's HIV-prevention drug Apretude approved by European Commission
07:19am, Tuesday, 19'th Sep 2023
The European Commission (EC) has authorised GSK PLC (LSE:GSK, NYSE:GSK) subsidiary ViiV Healthcare's HIV-prevention drug Apretude. Known scientifically as cabotegravir, Apretude can be used in combina
European Commission authorises GSK's HIV prevention drug
02:37am, Tuesday, 19'th Sep 2023
The European Commission has authorised GSK's HIV-focused unit ViiV Healthcare's cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.
GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia
10:32am, Monday, 18'th Sep 2023
GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States.
Incyte shares drop after FDA approves GSK's competing blood-cancer treatment
08:11am, Monday, 18'th Sep 2023
Incyte Corp. INCY, -1.47% shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK, +0.11% blood-cancer treatment, Ojjaara, that wil
US FDA approves GSK's anemia treatment
04:25pm, Friday, 15'th Sep 2023
British drugmaker GSK Plc said on Friday the U.S. Food and Drug Administration had approved its experimental drug to treat anemic patients with a type of bone marrow cancer called myelofibrosis.
EU regulator recommends to stop sale of GSK's blood cancer drug
08:56am, Friday, 15'th Sep 2023
The European Medicines Agency's human medicines committee on Friday recommended against renewal of the conditional marketing authorisation for GSK's blood cancer drug Blenrep.
GSK opens new site in UK unlike rival AstraZeneca
08:22am, Thursday, 14'th Sep 2023
GSK has opened a new £65 million drug factory in Hertfordshire in a move it said would enable rapid production of medicines developed through its research pipeline. In contrast to UK rival AstraZenec
GSK (GSK) Moves 5.5% Higher: Will This Strength Last?
05:16am, Monday, 11'th Sep 2023
GSK (GSK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
International Wide-Moat Stocks On Sale - The September 2023 Heat Map
09:05pm, Thursday, 07'th Sep 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th
GSK plc (GSK) Citi's 18th Annual BioPharma Conference Transcript
12:59pm, Thursday, 07'th Sep 2023
GSK plc (NYSE:GSK ) Citi's 18th Annual BioPharma Conference September 7, 2023 8:50 AM ET Company Participants Phil Dormitzer - SVP, Head of Vaccines R&D Conference Call Participants Andrew Baum - Citi
